Aarti Drugs delivers a steady Q2 performance, marking signs of a margin recovery and stronger export momentum. Revenue rose 9% YoY to ₹653 crore, while PAT surged 29% to ₹45 crore. EBITDA grew 26% YoY to ₹84.3 crore, with margins improving by 150 bps to 12.9%. APIs remained the key revenue driver at 79%, followed by formulations and specialty chemicals. The company’s focus on onco-therapy exports and cost optimization signals a positive turnaround ahead. With a market cap of ₹4,332 crore and promoter holding at 54.7%, Aarti Drugs is betting on export growth and product diversification to sustain profitability in coming quarters. The road ahead looks promising for this pharma midcap on the comeback trail.

See Full Page